- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01512186
A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther) (Panther)
A Phase II Study Investigating Upfront Pazopanib In Metastatic Clear Cell Renal Cancer (Panther)
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This is a Phase II, open label study evaluating pre-operative pazopanib treatment in previously untreated patients with metastatic clear cell renal cancer. This study follows a Simon 2 stage design
Patients will take pazopanib for 14 weeks followed by a nephrectomy. The drug will continue after nephrectomy until disease progression is documented. Patients will come off study once disease progression occurs, where they will then be followed for survival. Subsequent treatment at the discretion of the treating physician will be documented.
After surgery, all patients will be radiologically evaluated 8 weekly until progression. Standard radical nephrectomy with lymph node dissection will be performed on those patients who are deemed operable. The surgery can be laparoscopic or open. Those not deemed suitable for nephrectomy after 14 weeks of treatment will be offered a repeat biopsy.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
-
Basildon, Vereinigtes Königreich
- Basildon and Thurrock University Hospitals NHS Foundation Trust
-
Coventry, Vereinigtes Königreich
- University Hospitals Coventry & Warwickshire NHS Trust
-
Glasgow, Vereinigtes Königreich
- The Beatson West of Scotland Cancer Centre
-
London, Vereinigtes Königreich
- Barts and London Hospital NHS Trust
-
London, Vereinigtes Königreich
- Oncology & Clinical Haematology Trials Unit, Royal Free Hospital
-
London, Vereinigtes Königreich
- Oncology & Haematology Clinical Trials Unit, Guy's Hospital
-
Oxford, Vereinigtes Königreich
- Department of Oncology Oxford Cancer Centre
-
Southampton, Vereinigtes Königreich
- Southampton General Hospital
-
Southend, Vereinigtes Königreich
- Southend University Hospital Trust
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
Histopathologically confirmed clear cell carcinoma with measurable metastases on CT/MRI imaging (by RECIST v1.1). Only a component of clear cell is required.
- No prior systemic treatment or nephrectomy for RCC. Palliative radiotherapy is acceptable to non target lesions.
Adequate organ function as defined by the following criteria:
i. Total serum bilirubin ≤1.5 x uln (patients with gilbert's disease exempt) ii. Serum transaminases (ALT) <3 x uln iii. Calculated creatinine clearance >30ml/min iv. Absolute neutrophil count (ANC) ≥1000/mm3 without growth factor support v. Platelets ≥ 75,000/mm3
- Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment.
- Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures
- ECOG performance status of 0, 1 or 2.
- 18 years or above (no upper age limit) Male or female
Exclusion Criteria:
Congestive heart failure (class III or IV NYHA), myocardial infarction or coronary artery bypass graft/ stenting or stroke in the previous six months, ongoing severe or unstable arrhythmia requiring medication.
- Previous treatment for renal cancer
- Pregnancy or breastfeeding. Female patients must be surgically sterile, be postmenopausal, or must agree to use adequate contraception during the period of therapy.
- Male patients must be surgically sterile or agree to use adequate contraception during the period of therapy.
- Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would in the judgement of the investigator, impart excess risk associated with study participation or study drug administration, or which, in the judgement of the investigator, would make the patient inappropriate for entry into this study
- Prolonged QT interval >480msecs or a history of prolonged QT interval >480msecs
- Ongoing major gastrointestinal disease including ulcerative colitis, bleeding peptic ulcer disease or inflammatory bowel disease.
- Bleeding diathesis
- Current uncontrolled hypertension
- Another malignancy requiring treatment within the last 5 years. Local prostate cancer not requiring hormone therapy or an asymptomatic raised PSA is acceptable.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Clinical benefit of 14 weeks of pre-operative pazopanib therapy, prior to nephrectomy using RECIST 1.1 criteria
Zeitfenster: Interim analysis after 34 patients have 12 weeks of treatment
|
12 week CT scan will be compared to the baseline CT scan using RESIST criteria 1.1 to assess whether the patients have benefited from the upfront pazopanib treatment.
|
Interim analysis after 34 patients have 12 weeks of treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Surgical complications (blood loss, post operative complications, hospital stay)
Zeitfenster: After the first 20 patients have had a nephrectomy
|
Following surgery information regarding the quantity of blood loss, time the surgery took, length of hospital stay and whether there were any surgical complications will be recorded.
|
After the first 20 patients have had a nephrectomy
|
Overall Survival
Zeitfenster: After three years of study
|
Overall survival will be measured from start of treatment to time of death.
|
After three years of study
|
Progression free survival
Zeitfenster: After all patients have progresssed
|
Progression free survival will be measured from start of study treatment to time of disease progression.
|
After all patients have progresssed
|
Local response of primary tumour to pazopanib
Zeitfenster: After 12 weeks of study drug
|
After 12 weeks of study drug
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2009-016675-29
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Metastasierter klarzelliger Nierenkrebs
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRekrutierungNierenzellkarzinom | Chromophobes Nierenzellkarzinom | Papilläres Nierenzellkarzinom | Nicht klassifiziertes Nierenzellkarzinom | Collecting Duct Renal Cell Carcinoma | Translokation Nierenzellkarzinom | Nicht resezierbares fortgeschrittenes Nierenzellkarzinom | Metastasierendes Ncc-NierenzellkarzinomVereinigte Staaten
-
Memorial Sloan Kettering Cancer CenterAktiv, nicht rekrutierendChromophobes Nierenzellkarzinom | Papilläres Nierenzellkarzinom | Nicht klassifiziertes Nierenzellkarzinom | Fortgeschrittenes oder metastasiertes nicht-klarzelliges Nierenzellkarzinom | Fumarathydratase-defizientes Nierenzellkarzinom | Succinat-Dehydrogenase-defizientes Nierenzellkarzinom | Collecting Duct Renal Cell CarcinomaVereinigte Staaten